Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Gloria Borra
Observed names:
Borra, Gloria,
G Borra,
G. Borra
Institution:
Azienda Ospedaliero Universitaria Maggiore della Carita
Observed institutions:
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”,
Azienda Ospedaliero Universitaria Maggiore della Carita
ORCID:
0000-0002-7495-1461
Observed ORCID:
0000-0002-7495-1461
OpenAlex ID:
A5021435745
Crizotinib in MET -Deregulated or ROS1 -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial
2019
·
Lorenza Landi
, Rita Chiari
, et al.
·
Clinical Cancer Research
·
207
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
2017
·
Byoung Chul Cho
, Dong-Wan Kim
, et al.
·
Journal of Thoracic Oncology
·
178
PDF
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)–Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
2019
·
Byoung Chul Cho
, Radka Obermannova
, et al.
·
Journal of Thoracic Oncology
·
74
PDF
Emerging Targets in Advanced Non-Small-Cell Lung Cancer
2018
·
Francesco Valentino
, Gloria Borra
, et al.
·
Future Oncology
·
24
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer
2021
·
S. Novello
, V. Torri
, et al.
·
Annals of Oncology
·
22
PDF
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients
2019
·
Maria Lucia Reale
, Rita Chiari
, et al.
·
Lung Cancer
·
15
OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC
2017
·
B.C. Cho
, R. Obermannová
, et al.
·
Journal of Thoracic Oncology
·
14
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study
2019
·
E. Gobbini
, R. Chiari
, et al.
·
Clinical & Translational Oncology
·
6
Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial
2025
·
Lorenza Landi
, Rita Chiari
, et al.
·
JTO Clinical and Research Reports
·
3
PDF
Combi-TED: A new Trial Testing Tedopi ® with Docetaxel or Nivolumab in Metastatic Non-Small-Cell Lung Cancer Progressing After First Line
2022
·
Lorenza Landi
, Angelo Delmonte
, et al.
·
Future Oncology
·
3
EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial
2022
·
F. Cappuzzo
, R. Chiari
, et al.
·
Journal of Thoracic Oncology
·
3
PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results
2021
·
S. Novello
, V. Monica
, et al.
·
Journal of Thoracic Oncology
·
3
PDF
ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients
2020
·
Simona Carnio
, Annapaola Mariniello
, et al.
·
Journal of Molecular Pathology
·
3
PDF
203P Treatment patterns and real-world outcomes of extensive-stage small cell lung cancer: A retrospective, multicenter study
2024
·
M. Cani
, L. Buffoni
, et al.
·
ESMO Open
·
2
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
2017
·
Byoung Chul Cho
, Dong Wan Kim
, et al.
·
Newcastle University ePrints (Newcastle Univesity)
·
2
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry
2025
·
Francesco Passiglia
, Maria Lucia Reale
, et al.
·
The Oncologist
·
1
Combi-TED: A multicenter, phase II, open-label, randomized trial evaluating efficacy of OSE2021 plus docetaxel or OSE2021 plus nivolumab as second-line therapy in metastatic NSCLC progressing after first-line chemo-immunotherapy.
2022
·
Federico Cappuzzo
, Giulia Pasello
, et al.
·
Journal of Clinical Oncology
·
1
P84.05 Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial
2021
·
B.C. Cho
, D. Kim
, et al.
·
Journal of Thoracic Oncology
·
1
MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study.
2018
·
E. Gobbini
, P. Pizzutilo
, et al.
·
Journal of Thoracic Oncology
·
1
Listening understanding and acting (lung): focus on communicational issue in thoracic oncology
2018
·
Claudia Yvonne Finocchiaro
, Alessandra Rota
, et al.
·
Translational Cancer Research
·
1
Venous thromboembolism in non-small cell lung cancer patients: retrospective analysis of cases treated at the Oncology Day Hospital of Novara, Italy
2013
·
Roberta Buosi
, Gloria Borra
, et al.
·
Italian Journal of Medicine
·
1
PDF
Corrigendum to ’Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study’ [Cancer Treat Res Commun. 2026:47:101143]
2026
·
Paolo Bironzo
, Alessandro Morabito
, et al.
·
Cancer Treatment and Research Communications
PDF
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study
2026
·
Paolo Bironzo
, Alessandro Morabito
, et al.
·
Cancer Treatment and Research Communications
PDF
P1.07.51 Safety and Tolerability of Adjuvant Atezolizumab in Pd-L1>50% NSCLC Patients: Real-World Data From the Italian ATLAS Registry
2025
·
M.L. Reale
, F. Passiglia
, et al.
·
Journal of Thoracic Oncology
EP.06.80 Immunological Markers of Prognosis in Lung Cancer: T-Cell Subpopulations and Their Correlation With Clinical Outcomes
2025
·
L. Negrini
, F. Vezzoli
, et al.
·
Journal of Thoracic Oncology
Show more works
View as search
Works count:
46
Citation count:
565
H-index:
7
I10-index:
7
Year
Topic
Type